BRPI0416627A - combinação de compostos orgánicos - Google Patents
combinação de compostos orgánicosInfo
- Publication number
- BRPI0416627A BRPI0416627A BRPI0416627-2A BRPI0416627A BRPI0416627A BR PI0416627 A BRPI0416627 A BR PI0416627A BR PI0416627 A BRPI0416627 A BR PI0416627A BR PI0416627 A BRPI0416627 A BR PI0416627A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- pharmaceutically acceptable
- acceptable salt
- obesity
- diabetic
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 230000001771 impaired effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 229940125710 antiobesity agent Drugs 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 208000018631 connective tissue disease Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52056403P | 2003-11-17 | 2003-11-17 | |
| PCT/EP2004/012989 WO2005049088A2 (en) | 2003-11-17 | 2004-11-16 | Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0416627A true BRPI0416627A (pt) | 2007-01-16 |
Family
ID=34619485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0416627-2A BRPI0416627A (pt) | 2003-11-17 | 2004-11-16 | combinação de compostos orgánicos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070149451A1 (https=) |
| EP (1) | EP1687030A2 (https=) |
| JP (1) | JP2007511486A (https=) |
| KR (1) | KR20060109912A (https=) |
| CN (1) | CN1901938A (https=) |
| AU (2) | AU2004290896A1 (https=) |
| BR (1) | BRPI0416627A (https=) |
| CA (1) | CA2545514A1 (https=) |
| MX (1) | MXPA06005596A (https=) |
| RU (1) | RU2006121340A (https=) |
| WO (1) | WO2005049088A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| EP1617832B1 (en) | 2003-04-29 | 2008-03-12 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| EP2286840A3 (en) * | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Treatment of obesity and related diseases |
| AU2006239929B2 (en) | 2005-04-22 | 2011-11-03 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
| WO2007055743A2 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| DK2089005T3 (da) | 2006-11-09 | 2010-07-19 | Orexigen Therapeutics Inc | Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| AU2007324706B2 (en) | 2006-11-23 | 2013-09-05 | Sinoxa Pharma Gmbh | Pharmaceutical compositions for the treatment of capillary arteriopathy |
| US20100247491A1 (en) * | 2007-02-01 | 2010-09-30 | Christof Westenfelder | Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure |
| KR20100098628A (ko) * | 2007-11-14 | 2010-09-08 | 아밀린 파마슈티칼스, 인크. | 비만 및 비만 관련 질환 및 장애의 치료 방법 |
| WO2009151714A2 (en) * | 2008-03-24 | 2009-12-17 | Palatin Technologies, Inc. | Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| EP2437732B1 (en) * | 2009-06-05 | 2018-05-09 | VeroScience LLC | Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
| NZ612686A (en) | 2010-12-16 | 2015-11-27 | Cynapsus Therapeutics Inc | Sublingual films |
| WO2013125622A1 (ja) * | 2012-02-22 | 2013-08-29 | 森永乳業株式会社 | ジペプチジルペプチダーゼ－ｉｖ阻害剤 |
| JP5877560B2 (ja) * | 2012-03-09 | 2016-03-08 | 森永乳業株式会社 | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| CN110893181A (zh) | 2012-06-06 | 2020-03-20 | 纳丙药业有限责任公司 | 治疗超重和肥胖症的方法 |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| CN105920025B (zh) * | 2016-05-24 | 2018-11-06 | 华中科技大学同济医学院附属协和医院 | 托吡酯在治疗心肌梗死的药品中应用 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| BR112020013733A2 (pt) * | 2018-01-09 | 2020-12-01 | Gila Therapeutics, Inc. | composições e métodos para tratar doenças metabólicas |
| JP2021512051A (ja) | 2018-01-23 | 2021-05-13 | ギラ セラピューティクス インコーポレイテッドＧｉｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
| BR112022003686A2 (pt) | 2019-08-26 | 2022-05-24 | Period Pill Bv | Tratamento de sintomas induzidos pelo ciclo menstrual |
| EP4081201A4 (en) * | 2019-12-24 | 2024-01-10 | Aardvark Therapeutics Inc. | Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders |
| KR20250077661A (ko) | 2023-11-23 | 2025-06-02 | 재단법인 환동해산업연구원 | 항우울 및 항비만 효과를 가지는 해양생물자원 추출물 및 그 제조방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| WO1998032458A1 (en) * | 1997-01-23 | 1998-07-30 | Sumitomo Pharmaceuticals Company, Limited | Remedies for diabetes |
| US6060458A (en) * | 1998-02-13 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxyribonucleotides comprising O6 -benzylguanine and their use |
| PT1741446E (pt) * | 2000-01-21 | 2008-05-09 | Novartis Pharma Ag | Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos |
| US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| ATE395912T1 (de) * | 2001-03-27 | 2008-06-15 | Merck & Co Inc | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes |
| GB0109146D0 (en) * | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| ES2257555T3 (es) * | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
| ATE373660T1 (de) * | 2002-03-25 | 2007-10-15 | Merck & Co Inc | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes |
| US20040121964A1 (en) * | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
-
2004
- 2004-11-11 US US10/579,580 patent/US20070149451A1/en not_active Abandoned
- 2004-11-16 WO PCT/EP2004/012989 patent/WO2005049088A2/en not_active Ceased
- 2004-11-16 KR KR1020067009505A patent/KR20060109912A/ko not_active Withdrawn
- 2004-11-16 RU RU2006121340/15A patent/RU2006121340A/ru unknown
- 2004-11-16 JP JP2006538824A patent/JP2007511486A/ja not_active Withdrawn
- 2004-11-16 BR BRPI0416627-2A patent/BRPI0416627A/pt not_active IP Right Cessation
- 2004-11-16 MX MXPA06005596A patent/MXPA06005596A/es not_active Application Discontinuation
- 2004-11-16 CA CA002545514A patent/CA2545514A1/en not_active Abandoned
- 2004-11-16 EP EP04797931A patent/EP1687030A2/en not_active Withdrawn
- 2004-11-16 CN CNA200480040087XA patent/CN1901938A/zh active Pending
- 2004-11-16 AU AU2004290896A patent/AU2004290896A1/en not_active Abandoned
-
2009
- 2009-04-09 AU AU2009201408A patent/AU2009201408A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1901938A (zh) | 2007-01-24 |
| EP1687030A2 (en) | 2006-08-09 |
| RU2006121340A (ru) | 2007-12-27 |
| KR20060109912A (ko) | 2006-10-23 |
| CA2545514A1 (en) | 2005-06-02 |
| WO2005049088A2 (en) | 2005-06-02 |
| AU2004290896A1 (en) | 2005-06-02 |
| MXPA06005596A (es) | 2006-08-11 |
| WO2005049088A3 (en) | 2005-12-29 |
| US20070149451A1 (en) | 2007-06-28 |
| JP2007511486A (ja) | 2007-05-10 |
| AU2009201408A1 (en) | 2009-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0416627A (pt) | combinação de compostos orgánicos | |
| BR0311397A (pt) | Combinação de inibidor de dpp iv e um composto cardiovascular | |
| BRPI0516446A (pt) | combinação de compostos orgánicos | |
| KR102695135B1 (ko) | 글루코키나제 활성화제 및 dpp-iv 억제제를 포함하는 약제학적 병용물, 조성물 및 병용 제제, 및 이의 제조 방법 및 용도 | |
| CY1125006T1 (el) | Λιπαρα οξεα και η χρηση τους σε συνδυασμο με βιομορια | |
| Teixeira et al. | Safinamide: a new hope for Parkinson’s disease? | |
| AR047669A1 (es) | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion | |
| CR6742A (es) | Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo | |
| JP2015503539A5 (https=) | ||
| NO20076346L (no) | Fremgangsmater for forebygging og behandling av metabolske forstyrrelser og nye pyrazol-o-glykosidderivater | |
| BR0212852A (pt) | Combinações farmacêuticas de inibidores de pde-v e outros agentes | |
| WO2008031439A3 (en) | Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo [ 3.2. i ]octans such as steviol and isosteviol | |
| JP2007511486A5 (https=) | ||
| BRPI0517567A (pt) | composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto | |
| BR9913746F1 (pt) | derivado de piridínio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral, e, métodos de tratamento de um paciente diabético e de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento | |
| Williams et al. | 3′, 4′-Bis-difluoromethoxycinnamoylanthranilate (FT061): an orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy | |
| JP2018510916A (ja) | 医薬処方物 | |
| ATE481094T1 (de) | Behandlung von diabetischer nephropathie | |
| MX2025007329A (es) | Composicion farmaceutica para la prevencion o el tratamiento de la enfermedad de injerto contra huesped que contiene un derivado de glp-2 o un conjugado de accion prolongada del mismo | |
| AR073384A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion | |
| BRPI0416706A (pt) | composições farmacêuticas para o tratamento da disfunção, doença ou distúrbio renal, em particular em recipientes diabéticos | |
| Li et al. | Design, synthesis and biological evaluation of novel desloratadine derivatives with anti-inflammatory and H1 antagonize activities | |
| ECSP045460A (es) | Combinación de un inhibidor de dpp iv y un compuesto cardiovascular | |
| CA3277872A1 (en) | Pharmaceutical composition for the prevention or treatment of graft-versus-host disease containing glp-2 derivative or long-acting conjugate thereof | |
| Olyaei et al. | HMG-CoA reductase inhibitors in chronic kidney disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |